Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human Phase 1 single ascending dose study assessing ART2612

Next Previous
Trial Profile

First-in-human Phase 1 single ascending dose study assessing ART2612

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ART 2612 (Primary)
  • Indications Chemotherapy-induced damage; Peripheral neuropathies
  • Focus Adverse reactions; First in man

Most Recent Events

  • 30 Jun 2025 Results presented in the Artelo Biosciences media release.
  • 26 Jun 2025 According to Artelo Biosciences media release, the company announced it has entered into a definitive securities purchase agreement for an At-the-Market private placement for gross proceeds of approximately $1.425 million. The purpose of the offering was to provide sufficient capital for Artelo to announce clinical data regarding its two phase 1 study results for ART26.12 and a phase 2 study readout from the CAReS trial for ART27.13 as previously disclosed.
  • 02 Jun 2025 According to Artelo Biosciences media release, company expects to report results from a food effect study with ART26.12 this summer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top